ImmunityBio (NASDAQ:IBRX – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Earnings and Valuation
This table compares ImmunityBio and Tectonic Therapeutic”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ImmunityBio | $620,000.00 | 5,931.74 | -$583.20 million | ($0.97) | -5.44 |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.17) | -7.91 |
Tectonic Therapeutic has lower revenue, but higher earnings than ImmunityBio. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| ImmunityBio | -45,691.66% | N/A | -108.04% |
| Tectonic Therapeutic | N/A | -41.05% | -37.33% |
Volatility and Risk
ImmunityBio has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for ImmunityBio and Tectonic Therapeutic, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ImmunityBio | 0 | 1 | 0 | 1 | 3.00 |
| Tectonic Therapeutic | 0 | 0 | 4 | 1 | 3.20 |
ImmunityBio currently has a consensus target price of $4.75, suggesting a potential downside of 10.04%. Tectonic Therapeutic has a consensus target price of $60.00, suggesting a potential upside of 46.77%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than ImmunityBio.
Insider and Institutional Ownership
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Tectonic Therapeutic beats ImmunityBio on 8 of the 13 factors compared between the two stocks.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
